Abstract Selective and specific changes in gene expression characterize the end-stage failing heart. However, the pattern and relation of these changes to evolving systolic and diastolic dysfunction during development of heart failure remains undefined. In the present study, we assessed steady-state levels of mRNAs encoding a group of cardiac proteins during the early development of left ventricular dysfunction in dogs with pacing-induced cardiomyopathy. Corresponding hemodynamic assessments were made in the conscious state in the same animals and at the same time points at baseline, after 1 week of ventricular pacing, and at the onset of clinical heart failure. Systolic dysfunction dominated after 1 week of pacing, whereas diastolic dysfunction was far more pronounced with the onset of heart failure. Atrial natriuretic factor mRNA was undetectable in 7 of 12 hearts at baseline but was expressed in all hearts at 1 week (P<.01 by x2 test), and it increased markedly with progression to failure (P=.05). Creatine kix xrTilliam Osler1 first observed more than a cen-\J/ J tury ago that the pathophysiology of human VY s heart failure could be divided into three stages: (1) initial damage to the contractile apparatus, resulting in ventricular dysfunction, (2) a phase during which cardiovascular compensatory mechanisms are activated, and (3) 
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Abstract Selective and specific changes in gene expression characterize the end-stage failing heart. However, the pattern and relation of these changes to evolving systolic and diastolic dysfunction during development of heart failure remains undefined. In the present study, we assessed steady-state levels of mRNAs encoding a group of cardiac proteins during the early development of left ventricular dysfunction in dogs with pacing-induced cardiomyopathy. Corresponding hemodynamic assessments were made in the conscious state in the same animals and at the same time points at baseline, after 1 week of ventricular pacing, and at the onset of clinical heart failure. Systolic dysfunction dominated after 1 week of pacing, whereas diastolic dysfunction was far more pronounced with the onset of heart failure. Atrial natriuretic factor mRNA was undetectable in 7 of 12 hearts at baseline but was expressed in all hearts at 1 week (P<.01 by x2 test), and it increased markedly with progression to failure (P=.05). Creatine kix xrTilliam Osler1 first observed more than a cen-\J/ J tury ago that the pathophysiology of human VY s heart failure could be divided into three stages: (1) initial damage to the contractile apparatus, resulting in ventricular dysfunction, (2) a phase during which cardiovascular compensatory mechanisms are activated, and (3) loss of compensation with progressive deterioration in both systolic and diastolic function and eventual death. The availability of human myocardium explanted at the time of cardiac transplantation has recently enabled investigation into the molecular pathophysiology of the failing heart during the third and final stage of cardiac decompensation. Such studies have identified several mRNAs that are differentially regulated at the end stage of disease and therefore appear to be markers of the end-stage heart failure phenotype. Decreases in steady-state levels of mRNA encoding sarcoplasmic reticulum Ca2+-ATPase, 23 phospholamban,3'4 the dihydropyridine receptor,5 the Ca2' release channel,6 and the 3, -adrenergic receptor7 accompany reexpression of atrial natriuretic factoPf (ANF) in ventricular myocardium from patients with end-stage heart failure. In some cases, changes in the expression of these heart-failure marker genes have been accompanied by complementary alterations in the levels of the proteins encoded by these mRNAs,5-7 and there is evidence to suggest that changes in gene expression may be reversible with restitution of normal left ventricular function.8 However, these results reflect end-stage disease, with tissue obtained from patients having a variable duration of illness and varied pharmacologic therapy. There is virtually no information in either humans or large animals regarding the steady-state levels of similar "marker" mRNAs earlier in the course of heart-failure evolution, specifically during the first two stages delineated by Osler. Recent investigations suggest that large animals with pacing-induced cardiomyopathy provide a useful model that bears many similarities to human heart failure. Animals develop progressive biventricular dilation and failure after =3 to 5 weeks of pacing without evidence of either hypertrophy or ischemia.9-12Analogous to humans with congestive failure, diminished ventricular function in this model is associated with abnormal Ca2 handling13 and diminished function of the receptor-G proteinadenylyl cyclase transmembrane signaling complex.14 '15 Furthermore, studies of this model in larger animals facilitate repetitive in vivo evaluation of the evolution of failure at both the hemodynamic and molecular levels.
In the present study, we combined hemodynamic and molecular analysis in dogs during development of pacing-induced cardiomyopathy. The steady-state levels of the mRNAs encoding six cardiac proteins were assessed in endomyocardial biopsies obtained sequentially dur-ing the development of congestive failure, and the measurements were correlated with simultaneously measured longitudinal assessments of ventricular systolic and diastolic dysfunction in these animals.
Materials and Methods Animal Model
Twelve adult mongrel dogs (40 to 50 lb) were sedated with sodium thiamylal, intubated, and anesthetized with 1% to 2% halothane with continuous volume ventilation. Oxygen saturation and expired CO2 were maintained within the physiological range throughout surgery. After a left lateral thoracotomy incision, an arterial catheter was inserted into the descending thoracic aorta through a purse-string suture, and a venous catheter was placed in the right atrium via the right atrial appendage. A flexible tube (internal diameter, 1.5 With the exception of phospholamban, the primer pairs that were previously reported for the amplification of cDNAs from human and rat ventricular myocardium were not applicable to canine myocardium. Therefore, regions from the canine cDNAs of interest were used to design appropriate 3' and 5' (Table 1) . Amplification reactions with each of these primer pairs yielded a single band in an agarose gel, and the absolute identity of this band was confirmed by sequence analysis. The primer pairs were then incorporated into synthetic DNA constructs containing the bacteriophage T7 promoter at the 5' end and a polyadenine tract at the 3' end that served as templates for in vitro transcribed internal standards as previously described. 4 For assessment of steady-state levels of mRNA, 10 ,L of each PCR reaction mixture was removed during successive cycles of amplification (12 to 34) and electrophoresed in a 3% (wtlvol) NuSieve GTGO/0.5% (wt/vol) SeaKem LE (FMC BioProducts) gel containing Tris-acetate-EDTA and ethidium bromide. Samples were taken every other cycle for a total of nine samples. A Sau3A digest of pBluescript KS+ DNA (Bethesda Research Laboratories) was used as a molecular size standard. The gel was visualized with indirect UV radiation and photographed, and appropriate bands representing amplification products of the cDNA of interest and amplification products of the internal cDNA standard were cut out from the gel. Radioactivity in the bands was determined by Cerenkov counting, and the amount of radioactivity in each excised gel band was plotted against the number of PCR cycles.
Amplification of increasing concentrations of both internal DNA standard and sample DNA (reverse transcription products of the original RNA) was linear over several orders of magnitude. Preliminary experiments identified appropriate concentrations of each internal cDNA standard to allow for colinear amplification of the cDNA of interest and the appropriate standard cDNA when the initial reverse transcription reaction contained 1 spanned at least six amplification cycles. Under these conditions, the sensitivity of the assay for each primer pair was at least 3.4x105 molecules mRNA per microgram total RNA, and the assay was reproducible with a coefficient of variation of 12%.
With the exception of phospholamban, a gene having an intronless coding region, primers were designed to cross-splice junctions to abrogate amplification of contaminating genomic DNA. To exclude the presence of contaminating genomic DNA when assessing the levels of phospholamban mRNA, samples were amplified after deleting reverse transcriptase from the reaction constituents. No bands were detected in these samples, demonstrating the absence of significant genomic contamination.
Statistical Analysis
All data are presented as mean±SEM. Hemodynamic and mRNA data were compared by repeated-measures ANOVA using Dunnett's test for multiple comparisons. All data from all time points were entered into a single matrix, in which dummy variables were used to code for individual animals and time-point comparisons. This generated a pooled variance from the full data set and allowed for varying sample size at each time point. A value of P<.05 was considered to be statistically significant.
Morphological Assessment
Frozen specimens obtained at baseline and at the onset of congestive failure were shipped on dry ice and subsequently fixed in formalin, embedded in paraffin, and sectioned. Serial sections were stained with either picrosirius red or hematoxylin and eosin for analysis of collagen content and morphological assessment, respectively, as described previously in detail.28,29 Tissue was analyzed on a Quantimet 520 image analysis system. Contrast enhancement of picrosirius redstained sections was done by 540 -nm band-pass filter. Collagen content was assessed and quantified at x200 magnification. Evaluation was performed with observers blinded as to sample and time-point identity. Results Nine of the 12 dogs reached the early heart failure end point and therefore were evaluated at all three time points. In this group of animals, the final biopsy was obtained 25±3 days after pacing was initiated. Three dogs were found dead within 3 to 5 days of the week 1 evaluation, and these animals presumably expired suddenly; one animal expired just before final biopsy tissue was obtained.
Hemodynamic Responses
Substantial abnormalities in systolic dysfunction were observed after only 1 week of tachycardia pacing (Table  2) . Fractional shortening and dP/dtmax fell significantly, by 25% and 35%, respectively (both P<.01), with relatively little further decline after development of heart failure. In contrast, diastolic dysfunction, manifested by elevation of end-diastolic pressure and wall stress and prolongation of the time constant of relaxation, was not significant at 1 week but became prominent at the heart-failure time point (Table 2) .
Fig 1 displays example pressure-dimension loops
and relations in one dog. Multiple cardiac cycles are displayed at varying preloads, and the upper and lower boundaries (end-systolic and end-diastolic relations, respectively) are derived from these beats. Similar to the results of the steady-state analysis, the end-systolic pressure-dimension relation displayed a fall in slope and gradual shift rightward with worsening failure, consistent with contractile depression. Both this index and the stroke work-end-diastolic dimension relation index fell significantly early and remained reduced at heart failure ( Table 2 ). All hemodynamic results reported in Table 2 are identical to those obtained when only the animals that developed heart failure (n=8) were used.
Steady-State Levels of mRNA in Endomyocardial Biopsies
Individual mRNA responses for each gene in each animal are provided in Fig 2, baseline values in these animals. Repeated-measures ANOVA using only data from animals that completed the protocol yielded identical quantitative results, but with a P value for ANF increase at heart failure becoming borderline significant (P=.082). Although mean changes in CK-mito, Ca2+-ATPase, f3-MHC, and phospholamban were not significant when compared over time, it remained possible that changes in gene expression depended on the severity of diastolic and/or systolic dysfunction with failure rather than simply the time point of the observation. To test this possibility, we divided dogs into those that demonstrated a decrease in mRNA versus those with either unchanged or increased levels of expression, and we tested whether there were significant differences in end-diastolic pressure or dP/dtm., between these two subgroups. The results for phospholamban were notable. In the five dogs in which phospholamban mRNA fell, the mean change in end-diastolic pressure was +19±1.9 mm Hg as opposed to only +4.0±4.9 mm Hg for those in which mRNA levels did not fall (P=.02). Fig  3 displays the relation between end-diastolic pressure and phospholamban mRNA at baseline and heart failure for each dog demonstrating this dependence. In contrast, there was no significant disparity between dP/dtm,, responses in these subgroups. Similar analysis for the other mRNAs revealed no analogous dependencies for either end-diastolic pressure or dP/dt1a.
Morphological Analysis
To evaluate the possibility that changes in steadystate mRNA levels over time were myocardial biopsies were randomly selected at baseline and at the onset of heart failure and subjected to histological examination. Three of the specimens displayed normal myocytes, no infiltrates, and a collagen content of <2.1%. Of these, two were from hearts exhibiting heart failure, and one was from a baseline control heart. Three additional specimens demonstrated varying increased amounts of collagen (20.1%, 49.2%, and 4%). In the first case, a swirling appearance of the myocytes led us to speculate that the sample was likely obtained at a trabecula insertion site. In the sample with the most collagen, the remaining half of the sample appeared virtually normal, and this likely represented biopsy of a scarred area (due to prior biopsy). In the last case, there was also a small region of myocyte necrosis with cellular infiltrate and some reparative fibrosis. Of the latter three specimens, the first and last were from baseline control hearts. Thus, although there was variability in histological appearance, there was no consistent relation between time point and either collagen content, presence of inflammatory infiltrate, or myocyte dropout. In all cases, at least half the sample contained normal-appearing myocytes.
Discussion
Sequential hemodynamic evaluations in the present study by both standard steady-state measures (ie, dP/ dtm,x) and less load-dependent pressure-dimension relations were consistent with prior reports involving both anesthetized9 and conscious dogs.10 However, these measurements emphasize the finding that left ventricular systolic dysfunction predominates early after the initiation of tachycardia pacing, whereas diastolic dysfunction becomes more pronounced with the onset of clinical signs of congestive failure. Therefore, the tachycardia pacing model of heart failure provides a setting in which predominant early systolic dysfunction can be separated chronologically from later development of diastolic dysfunction. Some prior studies have demonstrated more substantial changes in left ventricular volume with progressive pacing13 when compared with the present data. This suggests that the results of the present study represent time points that are relatively early in the heart-failure phenotype.
The demonstration of increased ANF mRNA levels during the development of pacing-induced heart failure is not surprising, since reinduction of ANF expression is a ubiquitous finding in cardiac muscle diseases.30 However, the results of the present study are unique in that ANF gene expression was upregulated in a model characterized by an absence of myocardial hypertrophy.9Y10,3132 Reactivation of myocardial ANF expression can be induced by volume overload,33 pressure overload,34 and spontaneous hypertrophy35 and has been documented in end-stage failing human myocardium.4,8 However, ventricular activation of the ANF gene is probably a multifactorial phenomenon,36 as recent studies demonstrate that regional histological changes may trigger ANF expression in patients with hypertrophic cardiomyopathy, whereas hemodynamic overload serves as a trigger for reexpression in patients with hypertensive heart disease.37 Similarly, the finding that ANF gene reexpression occurred early after the induction of pacing is consistent with prior studies demonstrating a rapid rise in ANF mRNA levels shortly after initiation of hemodynamic overload.35 Indeed, the ANF gene contains cis-regulatory elements that recognize the immediate-early gene heterodimer c-foslc-jun.38
Creatine kinase (CK) enzymes exist as several isoforms in both skeletal and cardiac muscle, and these enzymes function in maintaining the proper intracellular ratio of ATP to ADP and the size of the phosphocreatine pool.39 Two CK genes encode the muscle (M) and brain (B) protein subunits that are present as either the homodimeric CK-MM and CK-BB or the heterodimeric CK-MB cytosolic isoenzymes.40 The CK-B-encoded isozymes predominate in fetal tissue; however, the CK-M-encoded isozyme makes up the majority of CK in mature tissues.41 The present study presents the first evidence that CK-B mRNA levels are increased in a model of failing myocardium that lacks myocyte hypertrophy.31 However, like ANF, it appears that CK-Bencoded protein is differentially regulated in many forms of heart muscle disease, since previous studies have demonstrated increases in CK-B-containing isozymes in dogs with cardiac hypertrophy42 and in dogs with coronary artery occlusion. 43 In addition, in rats with pressure overload of the left ventricle, the increase in CK-B-encoded protein was associated with a recapitulation of the fetal pattern of gene expression, as there was a substantial increase in CK-B mRNA.44 Increased CK-B mRNA and expressed protein levels may underlie a change to a more efficient energy utilization45 and improved chemomechanical efficiency in dogs with pacing-induced heart failure.12 Therefore, the increase in CK-B mRNA levels may mark adaptive responses in the failing myocardium.
Our inability to detect changes in 13 We cannot determine from the present data whether changes in ANF and CK-B gene expression that occur early in the development of pacing-induced heart failure are due to an increase in transcriptional activity or in mRNA stability. In addition, we cannot account for the presence of small but detectable amounts of both ANF and CK-B RNA in several of the baseline samples. Although both ANF and CK-B mRNA levels increased with initiation of pacing in these animals and baseline hemodynamic variables were normal, we cannot exclude the possibility that the earlier surgical instrumentation contributed to these baseline elevations. However, each animal served as its own control, baseline data were obtained nearly 2 weeks after surgery, and further increases in both CK-B and ANF mRNA levels were seen in animals with detectable levels at baseline. Finally, we cannot exclude the possibility that the changes in steady-state mRNA levels reported in the present study are limited to the endomyocardium. Indeed, recent studies suggest that the characteristic decrease in 13-adrenergic receptor density in failing human heart predominates in the endocardium and is not obvious in the epicardium.50 However, despite the endocardial localization of the decrease in 3-adrenergic density, there is a consensus that this decrease in ,l-receptor density accounts in large part for the insensitivity of the failing heart to adrenergic drive. 51 The increase in ANF mRNA was marked in two dogs; however, five dogs demonstrated at least a 200% rise in ANF mRNA, and four had more than a 10-fold increase. Similarly, CK-B mRNA levels rose by >200% in four dogs. Therefore, the results of our data do not reflect changes in only two dogs. Furthermore, it is interesting that there is no concordance between ANF and CK-B mRNA levels; ie, the dogs with the largest increases in ANF mRNA were not necessarily the same as the dogs with the greatest increase in CK-B mRNA. Finally, it is notable that there were generally consistent increases in ANF mRNA early in the development of heart failure. However, ANF mRNA declined or did not change in four of the eight animals between 1 week and congestive heart failure time points. Thus, there appears to be greater variability in the ANF responses later in heart failure, not with respect to baseline but in terms of the evolution of failure.
In summary, serial measurements of left ventricular function and steady-state levels of mRNA in dogs with pacing-induced heart failure demonstrate substantial abnormalities in systolic and diastolic performance and activation of both ANF and CK-B gene expression early in the development of congestive failure. Phospholamban mRNA levels decreased with the onset of clinical heart failure but only in those hearts demonstrating a substantial increase in left ventricular diastolic dysfunction. However, there was no change in the expression of Ca2+-ATPase, an mRNA that appears to be downregulated in the end-stage heart-failure phenotype in humans. Therefore, these results have led us to hypothesize that selective changes in gene expression can occur during the early development of heart failure in the tachycardia-paced dog that might not be reflective of the end-stage phenotype. Furthermore, our results demonstrate the importance of simultaneous measurements of gene expression and ventricular hemodynamics in the same animal and the usefulness of quantitative PCR for assessing gene expression in endomyocardial biopsy samples from large animal models of heart failure. Future studies of more chronic heart failure in this model may reveal closer similarities to the endstage changes in gene expression observed in humans.
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